UB ScholarWorks

Prep Adherence to Tenofovir-Based Therapeutics Seems Efficacious in Reducing HIV Infection Dissemination: A Comparative Evaluation on The Therapeutic Potency of Tenofovir-Based Prep & Dapivirine-Based Antiretroviral (ARV) Microbicide in HIV Prevention

Show simple item record

dc.contributor.author Paria, Ananya
dc.date.accessioned 2019-08-27T18:11:45Z
dc.date.available 2019-08-27T18:11:45Z
dc.date.issued 2019-08-25
dc.identifier.citation A. Paria, "Prep Adherence to Tenofovir-Based Therapeutics Seems Efficacious in Reducing HIV Infection Dissemination: A Comparative Evaluation on The Therapeutic Potency of Tenofovir-Based Prep & Dapivirine-Based Antiretroviral (ARV) Microbicide in HIV Prevention", Ph.D. dissertation, School of Health Science, Univ. of Bridgeport, Bridgeport, CT, 2019.
dc.identifier.uri https://scholarworks.bridgeport.edu/xmlui/handle/123456789/4252
dc.description This dissertation is being archived for campus access to current students and staff only at the request of the author.
dc.description.abstract HIV/AIDS is a serious public health issue causing millions of morbidities and thousands of mortalities with the immense socio-economic burden. This disease adversely impacts population science on a global scale. The development of an effective HIV vaccine remains a therapeutic challenge. Two principles pre-exposure prophylaxis (PrEP) approaches using Tenofovir-based, and Dapivirine-based therapeutic regimens are compared to HIV preventive efficacy in high-risk populations. This dissertation aims to determine if PrEP adherence to Tenofovir-based therapeutics as single or combined treatment approaches are more efficacious than Dapivirine microbicides-based therapeutic approaches in HIV prevention in high-risk populations. The trial outcomes are methodically segmented in four different therapeutic clusters of i) TDF-FTC, ii) TDF-alone, iii) 1% TFV gel, and iv) DVR to determine HIV preventive efficacy from individual treatment cluster, targeting 26,755 HIV uninfected high-risk populations. The cumulative HIV preventive therapeutic potency is assessed on a PICO table and measured conducting box plot and waterfall analyses. The results of this analysis demonstrated a 55% risk reduction from TDF-FTC combined treatment, 34% from TDF single treatment, 27% from TFV single treatment and 42% risk reduction from DVR Microbicides ring single treatment clusters. Men achieved the highest HIV preventive efficacy at 86% from the TDF-FTC group, whereas women achieved 71% of HIV preventive efficacy from the TDF-alone group. en_US
dc.language.iso en_US en_US
dc.publisher University of Bridgeport en_US
dc.subject Human immunodeficiency virus (HIV) prevention en_US
dc.subject Pre-exposure prophylaxis en_US
dc.subject High-risk populations en_US
dc.title Prep Adherence to Tenofovir-Based Therapeutics Seems Efficacious in Reducing HIV Infection Dissemination: A Comparative Evaluation on The Therapeutic Potency of Tenofovir-Based Prep & Dapivirine-Based Antiretroviral (ARV) Microbicide in HIV Prevention en_US
dc.type Thesis en_US
dc.institute.department School of Health Science en_US
dc.institute.name University of Bridgeport en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search ScholarWorks


Advanced Search

Browse

My Account